Merck initiates late-stage MS study
admin 11th September 2019 Uncategorised 0The previous Phase II trial met its primary endpoint. More: Merck initiates late-stage MS study Source: News
read moreThe previous Phase II trial met its primary endpoint. More: Merck initiates late-stage MS study Source: News
read moreThe pharma giant announced the “ground-breaking” RADIAN initiative at the Fast-Track Cities 2019 conference in London. More: Gilead, Elton John AIDS Foundation launch HIV initiative Source: News
read moreThousands of NHS patients could receive faster diagnosis and better treatment for life-changing diseases like cancer, dementia and Parkinson’s. More: Government injects £130m into cancer & debilitating illnesses Source: News
read moreMSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted. More: Kymriah leads latest round of SMC decisions Source: News
read moreAcadia was stung hard after its schizophrenia hopes for flagship Nuplazid fell flat back in late July. On the heels of that failure, Acadia is calling off a trial in dementia-related psychosis after it saw promising interim results for the
read moreRoche Tuesday unveiled results showing its Tecentriq-chemo combo failed to outdo solo chemo at extending the lives of previously untreated patients in squamous non-small cell lung cancer . More: WCLC: Roche's Tecentriq comes up short in squamous lung cancer, leaving
read more© 1994 - 2024 B.M. Pharmaceuticals